1
|
Arnold W, Blum A, Branyan J, Bruton TA, Carignan CC, Cortopassi G, Datta S, DeWitt J, Doherty AC, Halden RU, Harari H, Hartmann EM, Hrubec TC, Iyer S, Kwiatkowski CF, LaPier J, Li D, Li L, Muñiz Ortiz JG, Salamova A, Schettler T, Seguin RP, Soehl A, Sutton R, Xu L, Zheng G. Quaternary Ammonium Compounds: A Chemical Class of Emerging Concern. ENVIRONMENTAL SCIENCE & TECHNOLOGY 2023; 57:7645-7665. [PMID: 37157132 PMCID: PMC10210541 DOI: 10.1021/acs.est.2c08244] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 03/24/2023] [Accepted: 03/24/2023] [Indexed: 05/10/2023]
Abstract
Quaternary ammonium compounds (QACs), a large class of chemicals that includes high production volume substances, have been used for decades as antimicrobials, preservatives, and antistatic agents and for other functions in cleaning, disinfecting, personal care products, and durable consumer goods. QAC use has accelerated in response to the COVID-19 pandemic and the banning of 19 antimicrobials from several personal care products by the US Food and Drug Administration in 2016. Studies conducted before and after the onset of the pandemic indicate increased human exposure to QACs. Environmental releases of these chemicals have also increased. Emerging information on adverse environmental and human health impacts of QACs is motivating a reconsideration of the risks and benefits across the life cycle of their production, use, and disposal. This work presents a critical review of the literature and scientific perspective developed by a multidisciplinary, multi-institutional team of authors from academia, governmental, and nonprofit organizations. The review evaluates currently available information on the ecological and human health profile of QACs and identifies multiple areas of potential concern. Adverse ecological effects include acute and chronic toxicity to susceptible aquatic organisms, with concentrations of some QACs approaching levels of concern. Suspected or known adverse health outcomes include dermal and respiratory effects, developmental and reproductive toxicity, disruption of metabolic function such as lipid homeostasis, and impairment of mitochondrial function. QACs' role in antimicrobial resistance has also been demonstrated. In the US regulatory system, how a QAC is managed depends on how it is used, for example in pesticides or personal care products. This can result in the same QACs receiving different degrees of scrutiny depending on the use and the agency regulating it. Further, the US Environmental Protection Agency's current method of grouping QACs based on structure, first proposed in 1988, is insufficient to address the wide range of QAC chemistries, potential toxicities, and exposure scenarios. Consequently, exposures to common mixtures of QACs and from multiple sources remain largely unassessed. Some restrictions on the use of QACs have been implemented in the US and elsewhere, primarily focused on personal care products. Assessing the risks posed by QACs is hampered by their vast structural diversity and a lack of quantitative data on exposure and toxicity for the majority of these compounds. This review identifies important data gaps and provides research and policy recommendations for preserving the utility of QAC chemistries while also seeking to limit adverse environmental and human health effects.
Collapse
Affiliation(s)
- William
A. Arnold
- University
of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Arlene Blum
- Green
Science Policy Institute, Berkeley, California 94709, United States
- University
of California, Berkeley, California 94720, United States
| | - Jennifer Branyan
- California
Department of Toxic Substances Control, Sacramento, California 95814, United States
| | - Thomas A. Bruton
- California
Department of Toxic Substances Control, Sacramento, California 95814, United States
| | | | - Gino Cortopassi
- University
of California, Davis, California 95616, United States
| | - Sandipan Datta
- University
of California, Davis, California 95616, United States
| | - Jamie DeWitt
- East
Carolina University, Greenville, North Carolina 27834, United States
| | - Anne-Cooper Doherty
- California
Department of Toxic Substances Control, Sacramento, California 95814, United States
| | - Rolf U. Halden
- Arizona
State University, Tempe, Arizona 85287, United States
| | - Homero Harari
- Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | | | - Terry C. Hrubec
- Edward Via College of Osteopathic Medicine, Blacksburg, Virginia 24060, United States
| | - Shoba Iyer
- California Office of Environmental Health Hazard Assessment, Oakland, California 94612, United States
| | - Carol F. Kwiatkowski
- Green
Science Policy Institute, Berkeley, California 94709, United States
- North Carolina State University, Raleigh, North Carolina 27695 United States
| | - Jonas LaPier
- Green
Science Policy Institute, Berkeley, California 94709, United States
| | - Dingsheng Li
- University
of Nevada, Reno, Nevada 89557, United States
| | - Li Li
- University
of Nevada, Reno, Nevada 89557, United States
| | | | - Amina Salamova
- Indiana University, Atlanta, Georgia 30322, United States
| | - Ted Schettler
- Science and Environmental Health Network, Bolinas, California 94924, United States
| | - Ryan P. Seguin
- University of Washington, Seattle, Washington 98195, United States
| | - Anna Soehl
- Green
Science Policy Institute, Berkeley, California 94709, United States
| | - Rebecca Sutton
- San Francisco Estuary Institute, Richmond, California 94804, United States
| | - Libin Xu
- University of Washington, Seattle, Washington 98195, United States
| | - Guomao Zheng
- Southern University of Science and Technology, Shenzhen, Guangdong 518055, China
| |
Collapse
|
2
|
Wenzel C, Drozdzik M, Oswald S. Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction? Front Pharmacol 2021; 12:648388. [PMID: 33935750 PMCID: PMC8080103 DOI: 10.3389/fphar.2021.648388] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 03/01/2021] [Indexed: 01/11/2023] Open
Abstract
Intestinal transporter proteins are known to affect the pharmacokinetics and in turn the efficacy and safety of many orally administered drugs in a clinically relevant manner. This knowledge is especially well-established for intestinal ATP-binding cassette transporters such as P-gp and BCRP. In contrast to this, information about intestinal uptake carriers is much more limited although many hydrophilic or ionic drugs are not expected to undergo passive diffusion but probably require specific uptake transporters. A transporter which is controversially discussed with respect to its expression, localization and function in the human intestine is the organic cation transporter 1 (OCT1). This review article provides an up-to-date summary on the available data from expression analysis as well as functional studies in vitro, animal findings and clinical observations. The current evidence suggests that OCT1 is expressed in the human intestine in small amounts (on gene and protein levels), while its cellular localization in the apical or basolateral membrane of the enterocytes remains to be finally defined, but functional data point to a secretory function of the transporter at the basolateral membrane. Thus, OCT1 should not be considered as a classical uptake transporter in the intestine but rather as an intestinal elimination pathway for cationic compounds from the systemic circulation.
Collapse
Affiliation(s)
- Christoph Wenzel
- Department of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, Greifswald, Germany
| | - Marek Drozdzik
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland
| | - Stefan Oswald
- Institute of Pharmacology and Toxicology, Rostock University Medical Center, Rostock, Germany
| |
Collapse
|
3
|
Kolbow J, Modess C, Wegner D, Oswald S, Maritz MA, Rey H, Weitschies W, Siegmund W. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects. J Clin Pharmacol 2015; 56:239-45. [DOI: 10.1002/jcph.624] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 08/24/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Julia Kolbow
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Christiane Modess
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Danilo Wegner
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Stefan Oswald
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | | | - Hélène Rey
- Develco Pharma Schweiz AG; Pratteln Switzerland
| | - Werner Weitschies
- Department of Pharmaceutical Technology and Biopharmacy, Center of Drug Absorption and Transport; University of Greifswald; Greifswald Germany
| | - Werner Siegmund
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| |
Collapse
|
5
|
Tajiri S, Kanamaru T, Yoshida K, Hosoi Y, Konno T, Yada S, Nakagami H. The Relationship between the Drug Concentration Profiles in Plasma and the Drug Doses in the Colon. Chem Pharm Bull (Tokyo) 2010; 58:1295-300. [DOI: 10.1248/cpb.58.1295] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Shinichiro Tajiri
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Taro Kanamaru
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Kazuhiro Yoshida
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Yasue Hosoi
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Tsutomu Konno
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Shuichi Yada
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| | - Hiroaki Nakagami
- Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd
| |
Collapse
|
7
|
Sipes IG, Knudsen GA, Kuester RK. The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. Drug Metab Dispos 2007; 36:284-93. [PMID: 17967929 DOI: 10.1124/dmd.107.018515] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
These studies characterize the effect of dose and route of administration on the disposition and elimination of the ionic liquid, 1-butyl-3-methylimidazolium chloride (Bmim-Cl). After i.v. (5 mg/kg) or oral (50 mg/kg) administration to male F-344 rats [(14)C]Bmim-Cl detected in blood decreased rapidly. Clearance rates from the blood after i.v. and oral administration were similar (7.4 and 11.9 ml/min, respectively). Systemic bioavailability was determined to be 62.1% of a 50 mg/kg dose in rats. Urinary excretion of the parent compound by rats was the major route of elimination (i.v.: 91% in 24 h; oral: 55-74% in 24 h). The rates and routes of elimination were not affected by escalation of dose (0.5-50 mg/kg) or repeated oral administration (five daily administrations, 50 mg/kg) and were similar in male rats and B6C3F1 female mice (86-95% of dose eliminated in 24 h). Apparent systemic exposure to Bmim-Cl after dermal administration was dependent upon vehicle, as assessed by the percentage of dose eliminated in urine after application in a particular vehicle (water: 1%; ethanol/water: 3%; and dimethylformamide/water: 13% of dose). Regardless of gender, species, dose, route, or number of exposures, high-pressure liquid chromatography-UV/visible-radiometric analyses of urine samples showed a single peak that coeluted with the Bmim-Cl standard. These studies illustrate that systemic bioavailability of Bmim-Cl is high, tissue disposition and metabolism are negligible, and absorbed compound is extensively extracted by the kidney and eliminated in the urine as the parent compound.
Collapse
Affiliation(s)
- I G Sipes
- Department of Pharmacology, College of Medicine, The University of Arizona, P.O. Box 245050, Tucson, AZ 85724-5050, USA.
| | | | | |
Collapse
|
8
|
Kim MK, Shim CK. The transport of organic cations in the small intestine: current knowledge and emerging concepts. Arch Pharm Res 2006; 29:605-16. [PMID: 16903083 DOI: 10.1007/bf02969273] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
A wide variety of drugs and endogenous bioactive amines are organic cations (OCs). Approximately 40% of all conventional drugs on the market are OCs. Thus, the transport of xenobiotics or endogenous OCs in the body has been a subject of considerable interest, since the discovery and cloning of a family of OC transporters, referred to as organic cation transporter (OCTs), and a new subfamily of OCTs, OCTNs, leading to the functional characterization of these transporters in various systems including oocytes and some cell lines. Organic cation transporters are critical in drug absorption, targeting, and disposition of a drug. In this review, the recent advances in the characterization of organic cation transporters and their distribution in the small intestine are discussed. The results of the in vitro transport studies of various OCs in the small intestine using techniques such as isolated brush-border membrane vesicles, Ussing chamber systems and Caco-2 cells are discussed, and in vivo knock-out animal studies are summarized. Such information is essential for predicting pharmacokinetics and pharmacodynamics and in the design and development of new cationic drugs. An understanding of the mechanisms that control the intestinal transport of OCs will clearly aid achieving desirable clinical outcomes.
Collapse
Affiliation(s)
- Moon Kyoung Kim
- Laboratory of Transporters Targeted Drug Design, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Korea
| | | |
Collapse
|
9
|
Hong SS, Moon SC, Shim CK. Mechanism of intestinal transport of an organic cation, tributylmethylammonium in Caco-2 cell monolayers. Arch Pharm Res 2006; 29:318-22. [PMID: 16681038 DOI: 10.1007/bf02968577] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Many quaternary ammonium salts are incompletely absorbed after their oral administration and may also be actively secreted into the intestine. However, the underlying mechanism(s) that control the transport of these cations across the intestinal epithelium is not well understood. In this study, the mechanism of absorption of quaternary ammonium salts was investigated using Caco-2 cell monolayers, a human colon carcinoma cell line. Tributylmethyl-ammonium (TBuMA) was used as a model quaternary ammonium salts. When TBuMA was administrated at a dose of 13.3 imole/kg via iv and oral routes, the AUC values were 783.7 +/- 43.6 and 249.1 +/- 28.0 micormole x min/L for iv and oral administration, indicating a lower oral bioavailability of TBuMA (35.6%). The apparent permeability across Caco-2 monolayers from the basal to the apical side was 1.3 times (p < 0.05) greater than that from the apical to the basal side, indicating a net secretion of TBuMA in the intestine. This secretion appeared to be responsible for the low oral bioavailability of the compound, probably mediated by p-gp (p-glycoprotein) located in the apical membrane. In addition, the uptake of TBuMA by the apical membrane showed a Na+ dependency. Thus, TBuMA appears to absorbed via a Na+ dependent carrier and is then secreted via p-gp related carriers.
Collapse
Affiliation(s)
- Soon-Sun Hong
- Research Institute of Pharmaceutical Science & Department of Pharmaceutics, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
| | | | | |
Collapse
|